Back to News archiveVevey, Switzerland,Jul 10, 2014
As a result of the successful conclusion of the regulatory process and customary closing conditions, Nestlé today completed its acquisition of Valeant Pharmaceuticals International’s commercialisation rights to several key injectable aesthetic dermatology products in the US and Canada, as announced on 28 May 2014. These rights will be integrated into Nestlé Skin Health and commercialised by Galderma.
Based in Lausanne, Nestlé Skin Health is a global leader focused on enhancing the quality of life by delivering science-based solutions for the health of skin, hair and nails. Galderma, with approximately 5,000 employees and a presence in 80 countries, is the pharmaceutical arm of Nestlé Skin Health.
Media Robin Tickle Tel.: +41 21 924 22 00
Investors Tel.: +41 21 924 35 09
PDF press releases:
Galderma US press release:
Galderma finalizes major expansion in aesthetic and corrective dermatology in the US and Canada